July 2-30, 2025, Wednesdays from 1-2 p.m.
Virtual (Microsoft Teams)
The NIDA’s research training and career development team invites undergraduates, recent graduates, and early career scholars to join a 5-part virtual series to learn about graduate programs to consider and high priority areas within substance use and addiction research. Learn more about the sessions:
- July 2, 2025: "Should I Apply to Graduate School." Come ready to learn from Christie Brannock as she discusses different types of graduate programs, how to find them, the application process/timeline, and receive expert tips/advice on this next stage in your academic journey.
- July 9, 2025: Dr. Tisha Wiley from NIDA's Division of Epidemiology, Services and Prevention Research (DESPR) will be presenting on "Improving Treatment and Recovery Services for Adolescents & Young Adults." This seminar will cover approaches to addressing addiction in adolescents and young adults, including increasing uptake of effective interventions such as Medications for Opioid Use Disorder (MOUDs), engaging family and loved ones, and long-term recovery.
- July 16, 2025: NIDA substance use disorders (SUD) researchers and career development professionals including Drs. Catalina Lopez-Quintero, Charles Parry, Silvia Cruz, and Jeffrey Samet will engage in a panel discussion on "Identifying and Collaborating with Research Mentors.”
- July 23, 2025: Dr. Tristan McClure-Begley from NIDA's Division of Neuroscience and Behavior (DNB) will provide an in-depth discussion on “Quantifying Internal States Relevant to Substance Use" which will introduce behavioral pharmacology approaches used to study the effects of psychoactive substances, examples of commonly used addictive and therapeutic drugs, and how new technology is changing how we measure drug effects.
- July 30, 2025: Dr. Lorenzo Leggio from NIDA’s IRP will provide a presentation on “Unlocking New Treatments for Addiction: A Scientific Journey Through the Gut-Brain Axis” which will explore emerging basic, translational, and clinical evidence supporting the role of gut-brain neuroendocrine pathways (e.g., glucagon-like peptide-1) in addictive disorders, highlighting these pathways as potential targets for the development of novel treatments.